VTYX (Ventyx Biosciences) Future 3-5Y EPS without NRI Growth Rate : 10.61 (As of Mar. 25, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Ventyx Biosciences Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Ventyx Biosciences's Future 3-5Y EPS without NRI Growth Rate is 10.61.

Competitive Comparison of Ventyx Biosciences's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Ventyx Biosciences's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ventyx Biosciences's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ventyx Biosciences's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Ventyx Biosciences's Future 3-5Y EPS without NRI Growth Rate falls into.

Ventyx Biosciences (NAS:VTYX) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Ventyx Biosciences Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Ventyx Biosciences's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ventyx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ventyx Biosciences Inc (NAS:VTYX) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

12790 El Camino Real, Suite 200, San Diego, CA, USA, 92130

Website

https://www.ventyxbio.com

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Executives

John Nuss	officer: Chief Scientific Officer	C/O VENTYX BIOSCIENCES, INC., 332 ENCINITAS BLVD. SUITE 200, ENCINITAS CA 92024
Sheila Gujrathi	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Raju Mohan	director, officer: Chief Executive Officer	C/O VENTYX BIOSCINECES, INC., 332 ENCINITAS BLVD., SUITE 200, ENCINITAS CA 92024
Martin Auster	officer: Chief Financial Officer	C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
Christopher W Krueger	officer: Chief Business Officer	C/O ARDEA BIOSCIENCES INC, 2131 PALOMAR AIRPORT ROAD SUITE 300, CARLSBAD CA 92011
Nsv Partners Iii Lp	10 percent owner	500 WEST PUTNAM AVE, SUITE 400, GREENWICH CT 06830
Somu Subramaniam	director, 10 percent owner	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
William J. Sandborn	officer: See Remarks	C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
William Richard White	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Allison Hulme	director	C/O SOPHIRIS BIO INC., 1258 PROSPECT ST, LA JOLLA CA 92037
Venbio Global Strategic Fund Iii, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston	director, 10 percent owner	200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116